Revenue
2018
2019
2020
2021
2022
2023
2024
2025
COLLEGIUM PHARMACEUTICAL, INC (COLL)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M | $310.0M | $296.7M | $280.4M | $28.5M | $1.7M | — | — | — |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M | $179.8M | $103.0M | $114.7M | — | — | — | — | — |
| Research & development | — | $0 | $0 | $4.0M | $9.5M | $9.8M | $10.3M | $8.7M | $8.6M | $14.9M | $8.0M | $15.0M | $14.2M |
| Operating expenses | $283.6M | $207.4M | $159.2M | $176.2M | $133.0M | $123.6M | $126.8M | $135.4M | — | $95.8M | $26.9M | $17.7M | $16.0M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M | $56.2M | −$23.7M | −$20.7M | −$75.4M | −$94.1M | −$26.9M | −$17.7M | −$16.0M |
| EBITDAderived | $405.7M | $339.1M | $316.2M | — | $86.5M | $117.8M | −$23.0M | −$19.6M | −$74.9M | −$93.4M | −$26.7M | −$17.5M | — |
| Net income | $62.9M | $69.2M | $48.2M | −$25.0M | $71.5M | $26.8M | −$22.7M | −$39.1M | −$74.9M | −$94.2M | −$27.3M | −$17.9M | −$16.2M |
| Basic EPSper diluted share | $1.98 | $2.14 | $1.43 | -$0.74 | $2.05 | $0.78 | -$0.68 | -$1.19 | -$2.47 | -$3.88 | -$1.48 | -$22.72 | -$4.06 |
| Diluted EPSper diluted share | $1.73 | $1.86 | $1.29 | -$0.74 | $1.86 | $0.76 | -$0.68 | -$1.19 | -$2.47 | -$3.88 | -$1.48 | -$22.72 | -$4.06 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Freund John GordonDirector | SellCommon Stock | 20 | $34.05 | $681.00 | 84.0K |
| May 15, 2026Form 4 | Freund John GordonDirector | SellCommon Stock | 4.1K | $34.54 | $142.5K | 84.0K |
| May 13, 2026Form 4 | Lurker NancyDirector | SellCommon Stock | 4.5K | $35.97 | $161.9K | 18.0K |
| May 11, 2026Form 4 | BOHLIN GAREN GDirector | SellCommon Stock | 8.7K | $37.18 | $323.5K | 62.3K |
| Mar 18, 2026Form 4 · 10b5-1 | Dieter DavidEVP & General Counsel | SellCommon Stock | 14.0K | $34.92 | $488.0K | 77.1K |